Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer
-
Narrated by:
-
By:
About this listen
Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet